These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 37524506

  • 41. [Current state and future prospects of CAR T-cell therapy for myeloid malignancies].
    Saito S.
    Rinsho Ketsueki; 2024; 65(7):634-643. PubMed ID: 39098014
    [Abstract] [Full Text] [Related]

  • 42. [Development and functional verification of CAR-T cells targeting CLL-1].
    Chai X, Jin X, Zhao MF.
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb 14; 43(2):102-106. PubMed ID: 35381669
    [Abstract] [Full Text] [Related]

  • 43. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J, Hu H, Lian H, Yang S, Liu M, He J, Cao B, Chen D, Hu Y, Zhi C, Shen Y, Ye X, He B, Zhao M, Fan W, Xu L, Leidner R, Wu Q, Yang L, Zhang Z.
    Int J Biol Sci; 2024 Feb 14; 20(5):1578-1601. PubMed ID: 38481806
    [Abstract] [Full Text] [Related]

  • 44. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
    Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, Reid K, Spitler K, Yu B, Betts BC, Guevara-Patino JA, Maus MV, Davila ML.
    Mol Ther Oncolytics; 2023 Dec 19; 31():100751. PubMed ID: 38075241
    [Abstract] [Full Text] [Related]

  • 45. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
    Pratap S, Zhao ZJ.
    Cancer Rep (Hoboken); 2020 Apr 19; 3(2):e1222. PubMed ID: 32671999
    [Abstract] [Full Text] [Related]

  • 46. CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells.
    Jin X, Xie D, Sun R, Lu W, Xiao X, Yu Y, Meng J, Zhao M.
    Oncoimmunology; 2023 Apr 19; 12(1):2248826. PubMed ID: 37645216
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C, Röder J, Scherer A, Bodden M, Pfeifer Serrahima J, Bhatti A, Waldmann A, Müller N, Oberoi P, Wels WS.
    J Immunother Cancer; 2021 Oct 19; 9(10):. PubMed ID: 34599028
    [Abstract] [Full Text] [Related]

  • 50. Emerging Immunotherapy for Acute Myeloid Leukemia.
    Tabata R, Chi S, Yuda J, Minami Y.
    Int J Mol Sci; 2021 Feb 16; 22(4):. PubMed ID: 33669431
    [Abstract] [Full Text] [Related]

  • 51. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L, Liu X, Wang X, Sun Z, Song XT.
    Leuk Res; 2016 Feb 16; 41():76-84. PubMed ID: 26740053
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
    Zhang Y, Liang K, Zhou X, Zhang X, Xu H, Dai H, Song X, Yang X, Liu B, Shi T, Wei J.
    Cancer Sci; 2023 Jul 16; 114(7):2798-2809. PubMed ID: 37151176
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
    Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M.
    Front Immunol; 2022 Jul 16; 13():880108. PubMed ID: 35615350
    [Abstract] [Full Text] [Related]

  • 56. CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.
    Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM, Minden MD, Keating A.
    Haematologica; 2018 Oct 16; 103(10):1720-1729. PubMed ID: 29976748
    [Abstract] [Full Text] [Related]

  • 57. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
    Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR.
    Leukemia; 2009 Apr 16; 23(4):641-8. PubMed ID: 19151770
    [Abstract] [Full Text] [Related]

  • 58. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
    Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D.
    Leukemia; 2014 Aug 16; 28(8):1596-605. PubMed ID: 24504024
    [Abstract] [Full Text] [Related]

  • 59. Prospect of CAR T-cell therapy in acute myeloid leukemia.
    Badar T, Manna A, Gadd ME, Kharfan-Dabaja MA, Qin H.
    Expert Opin Investig Drugs; 2022 Feb 16; 31(2):211-220. PubMed ID: 35051347
    [Abstract] [Full Text] [Related]

  • 60. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
    Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz SC, Sendker S, Bartels N, Thomitzek A, Smorra D, Hejazi M, Uhrberg M, Scheckenbach K, Monzel C, Wiek C, Reinhardt D, Niktoreh N, Hanenberg H.
    Front Immunol; 2022 Feb 16; 13():847008. PubMed ID: 35464442
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.